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Atrial fibrillation is the most frequent complication after
coronary artery bypass surgery, occurring in up to 40% of
patients (1). It is even more common in those undergoing
valvular surgery, especially of the mitral valve, occurring in
as many as 64% of patients (2). Most episodes of atrial
fibrillation occur within the first few days after surgery, with
a peak incidence on postoperative days 2 to 3 (3). Although
postoperative atrial fibrillation is not usually associated with
significant morbidity and is often self-limited, it has a major
economic effect, increasing the length of hospital stay by up
to three days, with an additional cost of several thousand
dollars per patient (4,5).
A number of risk factors associated with an increased risk
of postoperative atrial fibrillation have been identified and
include age; atrial infarction and trauma resulting from
cannulation; postoperative electrolyte shifts, including po-
tassium and magnesium; pericarditis; right coronary artery
grafting; valvular heart disease; heightened postoperative
sympathetic tone; beta-adrenergic blocking agent with-
drawal; and chronic obstructive heart disease (5,6).
Despite the identification of a number of risk factors for
postoperative atrial fibrillation, prevention of this arrhyth-
mia has been problematic, and many prophylactic therapies,
including digoxin and calcium channel blocking agents,
have been found ineffective. Exceptions are the beta-
blockers, or drugs with beta-blocking activity, and a number
of studies have shown that beta-blockers, administered
before or immediately after surgery, are very effective for
preventing atrial fibrillation (7–9). Two meta-analyses have
confirmed that beta-blockers, regardless of the agent used,
the time of initiation or the dose administered, are an
effective prophylactic therapy, reducing the incidence of
atrial fibrillation from 34% and 20% to 8.7% and 9.8%,
respectively (10,11). Unfortunately, none of these trials
evaluated the influence of beta-blocking therapy on length
of stay or hospital cost.
Amiodarone, a class III antiarrhythmic drug that also has
beta-blocking activity, has also been shown to be an effective
prophylactic therapy, and in one trial of 124 patients
preoperative therapy begun at least seven days before surgery
reduced the incidence of atrial fibrillation compared with
placebo (53% vs. 25%) (12). Amiodarone therapy reduced
the duration of hospitalization (7.9 vs. 6.5 days), translating
into a decrease in hospital costs of $8,000. A second trial of
300 patients (ARCH), reported in 1998 at the American
College of Cardiology Annual Sessions, found that intrave-
nous amiodarone, administered immediately after surgery,
reduced the incidence of postoperative atrial fibrillation
compared with placebo (35.4% vs. 47.2%); however, length
of hospital stay was not reduced by amiodarone therapy.
Several studies have found that sotalol, another class III
agent with beta-blocking activity, begun after surgery is an
effective agent for preventing postoperative atrial fibrillation
when compared with placebo or metoprolol (13,14). The
study by Gomes et al. (15) published this month in the
Journal, in which oral sotalol therapy was administered
preoperatively, confirms and extends these observations.
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This study randomized 85 patients to sotalol or placebo;
therapy was begun 24 to 48 h before surgery and was
continued for four days after surgery. Compared with
placebo or a standard beta-blocker, which was administered
to 47% of patients in the placebo group, sotalol significantly
reduced the incidence of postoperative atrial fibrillation
(37.5% and 38.0% vs. 12.5%, respectively). It is important to
note that there were no episodes of torsades de pointes as a
result of sotalol therapy. However, the reduction in the
occurrence of atrial fibrillation with sotalol did not translate
into a reduction in hospital length of stay, which was
identical to that of placebo patients.
These results confirm the data from other studies in
which sotalol was administered postoperatively, that is,
sotalol is an effective therapy for preventing postoperative
atrial fibrillation and appears to be more effective than other
beta-blockers, perhaps because of its class III antiarrhythmic
activity. However, when the results of this and other trials
are compared, there does not appear to be a difference in the
effectiveness of sotalol when administered before or imme-
diately after surgery, as the incidence of atrial fibrillation
with sotalol (12.5%) is similar to that reported by other
studies in which sotalol therapy was administered postop-
eratively (range 10% to 16%).
Before these results are put into widespread clinical
practice, there are many issues to consider.
1. Many patients who undergo bypass surgery and are at
high risk for the development of atrial fibrillation were
excluded from this trial, including those with a left
ventricular ejection fraction ,28% or clinically evident
congestive heart failure, chronic obstructive pulmonary
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disease, impaired renal disease or first-degree or higher
atrioventricular block. Therefore, the data can only be
applied to a selected group of patients.
2. The role of conventional beta-blockers in the Gomes
study is uncertain, despite the finding in a small number
of patients that sotalol was more effective than conven-
tional beta-blockers. This is an important concern in
view of the substantial data from a number of other
studies suggesting that the incidence of postoperative
atrial fibrillation with prophylactic therapy using con-
ventional beta-blockers is low (8% to 10%) and is
equivalent to that seen in the current trial with sotalol
(10,11). It is therefore not clear that sotalol is more
effective than a standard beta-blocker.
An additional concern is that the doses of beta-
blockers administered in the Gomes trial were relatively
low. Without comparative data about the degree of beta
blockade achieved with conventional beta-blockers and
sotalol, such as the resting sinus heart rate, which is a
marker of beta blockade, it is unclear if the findings in
this trial are due to differences in the intensity of beta
blockade achieved in the different groups. As an exam-
ple, one study found that, compared with low doses of
propranolol and sotalol, higher doses of these drugs
were more effective for reducing the incidence of atrial
fibrillation; moreover, there was no difference between
these two agents when they were administered at
equivalent doses (16).
3. There were more patients who underwent valve re-
placement in the placebo group (18% vs. 10% in the
sotalol group). The incidence of postoperative atrial
fibrillation, even in those receiving therapy, is higher in
patients with valvular heart disease compared with
those with coronary artery disease (2). It is possible that
this may account for some of the observed differences in
outcome.
4. Although the incidence of atrial fibrillation in the
placebo group was 38%, the arrhythmia was paroxysmal
in 56% of these patients (duration 0.5 to 73 h). Because
paroxysmal atrial fibrillation is unlikely to be associated
with morbidity or to prolong hospitalization, it is
uncertain if such patients would derive benefit from any
prophylactic antiarrhythmic therapy.
5. It is not clear why there were no episodes of atrial
fibrillation after discontinuation of sotalol on day 4,
whereas those receiving placebo continued to have
episodes after this period of time. Sotalol has a half-life
of 8 to 12 h in patients without renal disease, and
therefore a prolonged drug effect is unlikely.
6. Although there were no cases of torsade de pointes in
this small study, this remains an important concern in
postoperative patients who often have electrolyte ab-
normalities, especially hypokalemia, which is an impor-
tant risk factor for drug-induced torsade de pointes
(17).
7. Most importantly, the reduction in postoperative atrial
fibrillation in the present study did not translate into a
reduction in the length of hospitalization, which is the
most important reason for the prevention of this ar-
rhythmia. Another important potential benefit from the
reduction in the incidence of atrial fibrillation is the
decreased risk for embolic stroke. However, the risk of
this complication associated with postoperative atrial
fibrillation is unknown, although likely to be low;
nevertheless, this study did not address this issue.
Since postoperative atrial fibrillation is often paroxysmal,
and it may revert spontaneously within several weeks in
those with arrhythmia that is still present at hospital
discharge, an alternative approach is initial rate control and
anticoagulation with pharmacologic or electric reversion at a
later time if atrial fibrillation persists (18). This strategy has
been found to reduce the duration and cost of hospitaliza-
tion and is safe, without a risk of bleeding complications or
thromboembolic events. It is possible that this may be the
best and safest approach to the management of postopera-
tive atrial fibrillation, reducing length of stay and hospital
cost and eliminating the potential risks associated with
antiarrhythmic drug therapy. It is hoped that future studies
will evaluate this approach and compare it with strategies
that involve arrhythmia prevention with antiarrhythmic
drugs.
Reprint requests and correspondence: Dr. Philip J. Podrid,
Section of Cardiology, Boston Medical Center, 1 Boston Medical
Center Place, Boston, Massachusetts 02118.
REFERENCES
1. Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and
conduction disturbances after coronary artery bypass graft surgery:
epidemiology, management and prognosis. Am Heart J 1995;129:
799 – 808.
2. Asher CR, Miller DP, Grimm RA, et al. Analysis of risk factors for
development of atrial fibrillation early after cardiac valvular surgery.
Am J Cardiol 1998;82:892–5.
3. Fuller JA, Adams GG, Buxton B. Atrial fibrillation after coronary
artery bypass grafting. Is it a disorder of the elderly? J Thorac
Cardiovasc Surg 1989;97:821–5.
4. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation
after coronary artery surgery. Current trends and impact on hospital
resources. Circulation 1996;94:390–7.
5. Creswell LL, Schuessler RB, Rosenbloom M, et al. Hazards of
postoperative atrial arrhythmias. Ann Thorac Surg 1993;56:539–49.
6. Leitch JW, Thomson D, Baird DK, et al. The importance of age as a
predictor of atrial fibrillation and flutter after coronary artery bypass
grafting. J Thorac Cardiovasc Surg 1990;100:338–42.
7. Mohr R, Smolinsky A, Goor DA. Prevention of supraventricular
arrhythmia with low-dose propranolol after coronary bypass. J Thorac
Cardiovasc Surg 1981;81:840–5.
8. Silverman NA, Wright R, Levitsky S. Efficacy of low-dose propranolol
in preventing post-operative supraventricular arrhythmias. Ann Surg
1982;196:194–7.
9. Khuri SF, Okike ON, Josa M, et al. Efficacy of nadolol in preventing
supraventricular tachycardia after coronary artery bypass grafting. Am J
Cardiol 1987;60:51D–8D.
10. Andrews TC, Reimold SC, Berlin JA, et al. Prevention of supraven-
tricular arrhythmias after coronary artery bypass surgery: a meta-
analysis of randomized control trials. Circulation 1991;84 Suppl
III:236–44.
341JACC Vol. 34, No. 2, 1999 Podrid
August 1999:340–2 Editorial Comment
11. Kowey PR, Taylor JE, Rials SL, Marinchak RA. Meta-analysis of the
effectiveness of prophylactic drug therapy in preventing supraventric-
ular arrhythmias early after coronary artery bypass grafting. Am J
Cardiol 1992;69:963–5.
12. Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone
as prophylaxis against atrial fibrillation after heart surgery. N Engl
J Med 1997;337:1785–91.
13. Suttorp MJ, Kingma JH, Peels HO, et al. Effectiveness of sotalol in
preventing supraventricular tachyarrhythmias shortly after coronary
artery bypass grafting. Am J Cardiol 1991;68:1163–9.
14. Parikka H, Toivonen L, Heikkila L, et al. Comparison of sotalol and
metoprolol in the prevention of atrial fibrillation after coronary artery
bypass surgery. J Cardiovasc Pharmacol 1998;31:67–73.
15. Gomes JA, Ip J, Santoni-Rugiu F, et al. Oral d,I sotalol reduces the
incidence of postoperative atrial fibrillation in coronary artery bypass
surgery patients: a randomized, double-blind, placebo-controlled
study. J Am Coll Cardiol 1999;34:334–9.
16. Suttorp MJ, Kingma JH, Gin TJ, et al. Efficacy and safety of low- and
high-dose sotalol versus propranolol in the prevention of supraventric-
ular tachyarrhythmias early after coronary artery bypass operations.
J Thorac Cardiovasc Surg 1990;100:921–6.
17. Roden DM. Taking the “idio” out of “idiosyncratic”: predicting
torsades de pointes. PACE 1998;21:1029–34.
18. Solomon AJ, Kouretas PC, Hopkins RA, et al. Early discharge of
patients with new-onset atrial fibrillation after cardiovascular surgery.
Am Heart J 1998;135:557–63.
342 Podrid JACC Vol. 34, No. 2, 1999
Editorial Comment August 1999:340–2
